Upender Velaparthi

Upender Velaparthi

Auto-generated profile, based on publicly available information

Upender Velaparthi

Bristol Myers Squibb

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2005 in Cancer Research
Verified
Journal Article
Open access
PDF file
JCJoan M. Carboni
Joan M. Carboni
ALAdrian V. Lee
Adrian V. Lee
DHDarryl L. Hadsell
Darryl L. Hadsell
BRBruce R. Rowley
Bruce R. Rowley
FLFrancis Y. Lee
Francis Y. Lee
TWTai W. Wong
Tai W. Wong
The insulin-like growth factor I receptor (IGF-IR) is a transmembrane tyrosine kinase that is essential to growth and development and also thought to provide a survival signal for the maintenance of the transformed phenotype. There has been increasing interest in further understanding the role of IGF-I signaling in cancer and in developing receptor antagonists for therapeutic application. We describe herein a novel animal model that involves transgenic expression of a fusion receptor that is constitutively activated by homodimerization. Transgenic mice that expressed the activated receptor showed aberrant development of the mammary glands and developed salivary and mammary adenocarcinomas as early as 8 weeks of age. Xenograft tumors and a cell line were derived from the transgenic animals and are sensitive to inhibition by a novel small-molecule inhibitor of the IGF-IR kinase. This new model should provide new opportunities for further understanding how aberrant IGF-IR signaling leads to tumorigenesis and for optimizing novel antagonists of the receptor kinase.

6 August 2005 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MWMark Wittman
Mark Wittman
JCJoan Carboni
Joan Carboni
RARicardo Attar
Ricardo Attar
BBBalu Balasubramanian
Balu Balasubramanian
×B× Praveen Balimane
× Praveen Balimane
DVDolatrai Vyas
Dolatrai Vyas

24 September 2009 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MWMark D. Wittman
Mark D. Wittman
JCJoan M. Carboni
Joan M. Carboni
ZYZheng Yang
Zheng Yang
FLFrancis Y. Lee
Francis Y. Lee
MAMelissa Antman
Melissa Antman
DVDolatrai M. Vyas
Dolatrai M. Vyas

1 April 2007 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
UVUpender Velaparthi
Upender Velaparthi
MWMark Wittman
Mark Wittman
PLPeiying Liu
Peiying Liu
KSKaren Stoffan
Karen Stoffan
KZKurt Zimmermann
Kurt Zimmermann
DVDolatrai Vyas
Dolatrai Vyas

1 January 1996 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
PHPeter D. Hobbs
Peter D. Hobbs
VUVelaparthi Upender
Velaparthi Upender
JLJyanwei Liu
Jyanwei Liu
DPDaniel J. Pollart
Daniel J. Pollart
DTDavid W. Thomas
David W. Thomas
MDMarcia I. Dawson
Marcia I. Dawson
The dimeric alkaloid michellamine B is synthesized streospecifically by the palladium-catalysed cross-coupling of the 6′-naphthaleneboronic acid of the tetrabenzylated derivative of korupensmine A and the 6′-bromo analogue of the tetrabenzylated derivative of korupensmine B, both of which are prepared by total synthesis.

1 August 1997 in Synlett
Verified
Journal Article
Closed access
PDF file
PHPeter D. Hobbs
Peter D. Hobbs
VUVelaparthi Upender
Velaparthi Upender
MDMarcia I. Dawson
Marcia I. Dawson
The total syntheses of two of the three dimeric naphthylisoquinoline michellamines - A and C - were achieved by Pd-catalyzed cross-coupling of the appropriate 6'-bromo- or 6'-boronic acid-substituted tetrabenzylated korupsensamine A and B derivatives under nonaqueous conditions, followed by deprotection of the octabenzylated products.